126 related articles for article (PubMed ID: 1913342)
1. Modulation of Clostridium difficile induced mortality as a function of the dose and the viability of the Saccharomyces boulardii used as a preventative agent in gnotobiotic mice.
Elmer GW; Corthier G
Can J Microbiol; 1991 Apr; 37(4):315-7. PubMed ID: 1913342
[TBL] [Abstract][Full Text] [Related]
2. Prevention of Clostridium difficile-induced experimental pseudomembranous colitis by Saccharomyces boulardii: a scanning electron microscopic and microbiological study.
Castex F; Corthier G; Jouvert S; Elmer GW; Lucas F; Bastide M
J Gen Microbiol; 1990 Jun; 136(6):1085-9. PubMed ID: 2200843
[TBL] [Abstract][Full Text] [Related]
3. Prevention of Clostridium difficile induced mortality in gnotobiotic mice by Saccharomyces boulardii.
Corthier G; Dubos F; Ducluzeau R
Can J Microbiol; 1986 Nov; 32(11):894-6. PubMed ID: 3815159
[TBL] [Abstract][Full Text] [Related]
4. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa.
Castagliuolo I; Riegler MF; Valenick L; LaMont JT; Pothoulakis C
Infect Immun; 1999 Jan; 67(1):302-7. PubMed ID: 9864230
[TBL] [Abstract][Full Text] [Related]
5. Bacillus amyloliquefaciens as prophylactic treatment for Clostridium difficile-associated disease in a mouse model.
Geeraerts S; Ducatelle R; Haesebrouck F; Van Immerseel F
J Gastroenterol Hepatol; 2015 Aug; 30(8):1275-80. PubMed ID: 25800047
[TBL] [Abstract][Full Text] [Related]
6. Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants.
Buts JP; Corthier G; Delmee M
J Pediatr Gastroenterol Nutr; 1993 May; 16(4):419-25. PubMed ID: 8315551
[TBL] [Abstract][Full Text] [Related]
7. Clostridium difficile typhlitis associated with cecal mucosal hyperplasia in Syrian hamsters.
Ryden EB; Lipman NS; Taylor NS; Rose R; Fox JG
Lab Anim Sci; 1991 Dec; 41(6):553-8. PubMed ID: 1667196
[TBL] [Abstract][Full Text] [Related]
8. Experimental effects of Saccharomyces boulardii on diarrheal pathogens.
Czerucka D; Rampal P
Microbes Infect; 2002 Jun; 4(7):733-9. PubMed ID: 12067833
[TBL] [Abstract][Full Text] [Related]
9. Brewer's yeast and Saccharomyces boulardii both attenuate Clostridium difficile-induced colonic secretion in the rat.
Izadnia F; Wong CT; Kocoshis SA
Dig Dis Sci; 1998 Sep; 43(9):2055-60. PubMed ID: 9753273
[TBL] [Abstract][Full Text] [Related]
10. Effect of toxins produced by various Clostridium difficile strains on cecum size reduction in gnotobiotic mice.
Mahé S; Corthier G
Can J Microbiol; 1988 Jul; 34(7):916-8. PubMed ID: 3143476
[TBL] [Abstract][Full Text] [Related]
11. Prevention of further recurrences of Clostridium difficile colitis with Saccharomyces boulardii.
Kimmey MB; Elmer GW; Surawicz CM; McFarland LV
Dig Dis Sci; 1990 Jul; 35(7):897-901. PubMed ID: 2364845
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of a mixture of kefir-isolated lactic acid bacteria and yeasts in a hamster model of Clostridium difficile infection.
Bolla PA; Carasi P; Bolla Mde L; De Antoni GL; Serradell Mde L
Anaerobe; 2013 Jun; 21():28-33. PubMed ID: 23542116
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study.
Can M; Beşirbellioglu BA; Avci IY; Beker CM; Pahsa A
Med Sci Monit; 2006 Apr; 12(4):PI19-22. PubMed ID: 16572062
[TBL] [Abstract][Full Text] [Related]
14. Suppression by Saccharomyces boulardii of toxigenic Clostridium difficile overgrowth after vancomycin treatment in hamsters.
Elmer GW; McFarland LV
Antimicrob Agents Chemother; 1987 Jan; 31(1):129-31. PubMed ID: 3566236
[TBL] [Abstract][Full Text] [Related]
15. Clostridium difficile colitis.
Fang FC; Madinger NE
N Engl J Med; 1994 Jun; 330(24):1754; author reply 1755. PubMed ID: 8190139
[No Abstract] [Full Text] [Related]
16. Recurrent Clostridium difficile infection in a patient with selective IgG1 deficiency treated with intravenous immune globulin and Saccharomyces boulardii.
Hassett J; Meyers S; McFarland L; Mulligan ME
Clin Infect Dis; 1995 Jun; 20 Suppl 2():S266-8. PubMed ID: 7548571
[No Abstract] [Full Text] [Related]
17. Saccharomyces boulardii for the prevention of hospital onset Clostridium difficile infection.
Flatley EA; Wilde AM; Nailor MD
J Gastrointestin Liver Dis; 2015 Mar; 24(1):21-4. PubMed ID: 25822430
[TBL] [Abstract][Full Text] [Related]
18. Effect of various diets on toxin production by two strains of Clostridium difficile in gnotobiotic mice.
Mahe S; Corthier G; Dubos F
Infect Immun; 1987 Aug; 55(8):1801-5. PubMed ID: 3610315
[TBL] [Abstract][Full Text] [Related]
19. Clostridium difficile and its cytotoxin in diarrhoeic stools of hospitalized patients. Toxigenic potential of the isolates.
De Barbeyrac B; Guinet R; Quentin C; Cantet P; Bebear C
Ann Biol Clin (Paris); 1989; 47(2):67-70. PubMed ID: 2660635
[TBL] [Abstract][Full Text] [Related]
20. Effect of oral Saccharomyces boulardii treatment on the activity of Clostridium difficile toxins in mouse digestive tract.
Corthier G; Lucas F; Jouvert S; Castex F
Toxicon; 1992 Dec; 30(12):1583-9. PubMed ID: 1488767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
